Intermittent administration of the circulating form of human parathyroid hormone (hPTH-1-37) prevents bone loss in ovariectomized rats.
The circulating hormonal form of human parathyroid hormone (hPTH-1-37) has been assessed in vitro as well as in vivo in the ovariectomized rat, a model for postmenopausal osteoporosis. In vitro, hPTH-1-37 induces a dose-dependent cAMP formation and increases vitality as well as alkaline phosphatase activity in UMR106 osteosarcoma cells. Differentiation and proliferation of osteoclasts in rat bone marrow-derived stem cell preparations are decreased. Daily hPTH-1-37 s.c. administration in ovariectomized rats for 60 days results in augmented formation of new bone, in amplified femural bone density, and in thickening of the calvaria.
Stephan
S
S
IPF PharmaCeuticals GmbH, Hannover, Germany.
van de Flierdt
J
J
Loumi
S
S
Bonaterra
G
G
Kramer
F-J
FJ
Fehr
M
M
Tillmann
H-C
HC
Forssmann
W G
WG
Maronde
Erik
E
D000469:Alkaline Phosphatase / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D045744:Cell Line, Tumor; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging / Q000187:drug effects / Q000254:growth & development; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D011859:Radiography; D051381:Rats; D017208:Rats, Wistar; D012886:Skull / Q000187:drug effects / Q000254:growth & development
D010281:Parathyroid Hormone; D010446:Peptide Fragments; C094316:parathyroid hormone (1-37); D000242:Cyclic AMP; D000469:Alkaline Phosphatase